Hellings P W, Lau S, Scadding G K, Bjermer L, Backer V, Chaker A M, Conti D M, De Corso E, Diamant Z, Djukanovic R, Fokkens W, Gevaert P, Gray C L, Han J K, Heaney L G, Hoffmann H J, Jesenak M, Johansen P, Kumaran M S, McDonald M, Melén E, Mullol J, Reitsma S, Ryan D, Scadding G, Schmid-Grendelmeier P, Teeling T, Odemyr M, Wahn U
Department of Otorhinolaryngology-Head and Neck Surgery, University Hospitals, Leuven, Belgium.
Upper Airways Research Laboratory, Department of Head and Skin, Ghent University, Ghent, Belgium.
Front Allergy. 2023 Jul 27;4:1236977. doi: 10.3389/falgy.2023.1236977. eCollection 2023.
In March 2023, the European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) organized its bi-annual Summit in Brussels with expert panel members of EUFOREA, representatives of the EUFOREA patient advisory board, and the EUFOREA board and management teams. Its aim was to define the research, educational and advocacy initiatives to be developed by EUFOREA over the next 2 years until the 10th anniversary in 2025. EUFOREA is an international non-for-profit organization forming an alliance of all stakeholders dedicated to reducing the prevalence and burden of chronic allergic and respiratory diseases via research, education, and advocacy. Based on its medical scientific core competency, EUFOREA offers an evidence-supported platform to introduce innovation and education in healthcare leading to optimal patient care, bridging the gap between latest scientific evidence and daily practice. Aligned with the mission of improving health care, the expert panels of asthma, allergic rhinitis (AR), chronic rhinosinusitis (CRS) & European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS), allergen immunotherapy (AIT) and paediatrics have proposed and elaborated a variety of activities that correspond to major unmet needs in the allergy and respiratory field. The current report provides a concise overview of the achievements, ambitions, and action plan of EUFOREA for the future, allowing all stakeholders in the allergy and respiratory field to be up-dated and inspired to join forces in Europe and beyond.
2023年3月，欧洲过敏与气道疾病研究和教育论坛（EUFOREA）在布鲁塞尔举办了其两年一度的峰会，参会人员包括EUFOREA专家小组成员、EUFOREA患者咨询委员会代表以及EUFOREA董事会和管理团队。峰会旨在确定EUFOREA在2025年十周年之前未来两年内要开展的研究、教育和宣传倡议。EUFOREA是一个国际非营利组织，由所有利益相关者组成联盟，致力于通过研究、教育和宣传来降低慢性过敏性和呼吸道疾病的患病率和负担。基于其医学科学核心能力，EUFOREA提供一个有证据支持的平台，在医疗保健领域引入创新和教育，以实现最佳的患者护理，弥合最新科学证据与日常实践之间的差距。为配合改善医疗保健的使命，哮喘、过敏性鼻炎（AR）、慢性鼻-鼻窦炎（CRS）与《欧洲鼻窦炎和鼻息肉立场文件》（EPOS）、变应原免疫疗法（AIT）以及儿科学领域的专家小组提出并阐述了一系列与过敏和呼吸领域主要未满足需求相对应的活动。本报告简要概述了EUFOREA未来的成就、目标和行动计划，使过敏和呼吸领域的所有利益相关者能够了解最新情况并受到鼓舞，在欧洲及其他地区携手合作。
